122P Abemaciclib in HR+/HER2- metastatic breast cancer: A real-world experience
Michele Bottosso(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Federica Miglietta(University of Padua), Alice Menichetti(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Ottavia Amato, Caterina Barbieri(Vita-Salute San Raffaele University), Maria Vittoria Dieci(Istituto Oncologico Veneto), Elisa Genovesi(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Enrico Cumerlato(University of Padua)
Cited by 2
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk
|Nature Genetics|2017|642
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290